This article is more than 5 years old. Information may no longer be current.

AcuFocus secures $21 million in funding, seeks international growth

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

AcuFocus announced it has secured $21 million in funding, according to a company press release.

All existing investors, which include HealthCare Royalty Partners, SV Life Sciences, Versant Ventures, Carlyle Group, Accuitive Medical Ventures and Medtronic, participated in the financial gain.

The company plans to use the funds to continue international growth strategies and advance research and development projects, according to the release.

“While we work closely with the [U.S. Food and Drug Administration] on advancing our PMA submission for the Kamra inlay, we are taking steps to expand our sales and marketing organization,” Jim Mazzo, AcuFocus’ executive chairman and CEO, said in the release. “We are also focusing significant R&D resources on development of a new presbyopia-correcting [IOL] that we plan to introduce soon.”

The FDA’s Ophthalmic Devices Panel recommended approval for AcuFocus’ Kamra inlay for the treatment of presbyopia in June.